Bausch Health Companies Inc. (BHC)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 6.29 |
| Open | 6.30 |
| Bid | 6.26 x 1400 |
| Ask | 6.65 x 4000 |
| Day's Range | 6.27 - 6.57 |
| 52 Week Range | 6.09 - 11.46 |
| Volume | |
| Avg. Volume | 3,063,858 |
| Market Cap | 2.406B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | 9.83 |
- Baystreet
Markets Finish Day on Upswing
Equity markets throughout North America found late strength Friday, and progressed into positive territory, ...
ACCESSWIREBausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced additional Canadian public drug plan listings for Pr UCERIS ® (budesonide) aerosol foam to treat mild to ...
ACCESSWIRESalix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod ...
© 2024 Yahoo. All rights reserved.